Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafi Emmanuel

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Nature Genetics|February 26, 2015
YAP and the drug resistance highwayAlona Keren-Paz, Rafi Emmanuel, Yardena Samuels
Cancer Letters|April 30, 2013
eIF3c: a potential therapeutic target for cancerRafi Emmanuel, Shiri Weinstein, Dalit Landesman-Milo, et al.
ACS Nano|February 6, 2014
Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clustersKeren Cohen, Rafi Emmanuel, Einat Kisin-Finfer, et al.
Nucleic Acids Research|January 3, 2012
Identification of CTCF as a master regulator of the clustered protocadherin genesMichal Golan-Mashiach, Moshe Grunspan, Rafi Emmanuel, et al.
Pigment Cell & Melanoma Research|April 18, 2018
Refinement of the endogenous epitope tagging technology allows the identification of a novel NRAS binding partner in melanomaMichal Alon, Rafi Emmanuel, Nouar Qutob, et al.
Molecular and Cellular Biology|June 7, 2017
Efficient and Accurate Translation Initiation Directed by TISU Involves RPS3 and RPS10e Binding and Differential Eukaryotic Initiation Factor 1A RegulationOra Haimov, Hadar Sinvani, Franck Martin, et al.
Plos One|August 21, 2012
RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphomaShiri Weinstein, Rafi Emmanuel, Ashley M Jacobi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2015
Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignanciesShiri Weinstein, Itai A Toker, Rafi Emmanuel, et al.
Molecular Therapy. Methods & Clinical Development|July 7, 2022
Mutant allele knockout with novel CRISPR nuclease promotes myelopoiesis in ELANE neutropeniaPeter Sabo, Vahagn Makaryan, Yosef Dicken, et al.
Oncotarget|June 11, 2014
A highly recurrent RPS27 5'UTR mutation in melanomaKen Dutton-Regester, Jared J Gartner, Rafi Emmanuel, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Nature Genetics|February 26, 2015
YAP and the drug resistance highwayAlona Keren-Paz, Rafi Emmanuel, Yardena Samuels
Cancer Letters|April 30, 2013
eIF3c: a potential therapeutic target for cancerRafi Emmanuel, Shiri Weinstein, Dalit Landesman-Milo, et al.
ACS Nano|February 6, 2014
Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clustersKeren Cohen, Rafi Emmanuel, Einat Kisin-Finfer, et al.
Nucleic Acids Research|January 3, 2012
Identification of CTCF as a master regulator of the clustered protocadherin genesMichal Golan-Mashiach, Moshe Grunspan, Rafi Emmanuel, et al.
Pigment Cell & Melanoma Research|April 18, 2018
Refinement of the endogenous epitope tagging technology allows the identification of a novel NRAS binding partner in melanomaMichal Alon, Rafi Emmanuel, Nouar Qutob, et al.
Molecular and Cellular Biology|June 7, 2017
Efficient and Accurate Translation Initiation Directed by TISU Involves RPS3 and RPS10e Binding and Differential Eukaryotic Initiation Factor 1A RegulationOra Haimov, Hadar Sinvani, Franck Martin, et al.
Plos One|August 21, 2012
RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphomaShiri Weinstein, Rafi Emmanuel, Ashley M Jacobi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2015
Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignanciesShiri Weinstein, Itai A Toker, Rafi Emmanuel, et al.
Molecular Therapy. Methods & Clinical Development|July 7, 2022
Mutant allele knockout with novel CRISPR nuclease promotes myelopoiesis in ELANE neutropeniaPeter Sabo, Vahagn Makaryan, Yosef Dicken, et al.
Oncotarget|June 11, 2014
A highly recurrent RPS27 5'UTR mutation in melanomaKen Dutton-Regester, Jared J Gartner, Rafi Emmanuel, et al.
Pageof 2